Recombinant Expression and Purification of Human Cystatin C Biomarker in *Escherichia coli* for Prediagnostic Renal Disorders

Zahra Abdollahi, Samaneh Khodi, Elaheh Gheybi, Jafar Amani, Ali Karami

1Applied Biotechnology Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
2Department of Biology, Faculty of Science, University of Guilan, Rasht, Iran
3Applied Microbiology Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
4Molecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

**Corresponding Authors:** Jafar Amani, PhD, Associate Professor, Applied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Vanak Sq. Molasadra St. Tehran, Iran. Tel: +98-21-82482392, Fax: +98-21-88068924, Email: jafar.amani@gmail.com
Ali Karami, PhD, Professor, Molecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Molasadra St. Vanaq Sq. Tehran, Iran. Tel: +98-21-88039883, Fax: +98-21-8057023, Email: alikarami1@yahoo.com

**Abstract**

**Introduction:** Chronic kidney disease is a worldwide health problem and Glomerular filtration rate (GFR) is the most frequently used criteria in the assessment of renal function. Cystatin C as a member of type 2 cystatin superfamily and cysteine-protease inhibitor is found in high concentrations in all biological fluids. This study is aimed to study cystatin C as a potent biomarker for clinical measurement of renal disorders and other diseases.

**Materials and Methods:** In this study, the human cystatin C construct was analyzed by bioinformatics software. It was cloned and expressed to produce an appropriate antigen for anti-cystatin C (anti-Cys C) obtained from mice Balb/C as a crucial point in the improvement of an enzyme-linked immunosorbent assay (ELISA) method. Serum samples were given from 32 hospitalized patients with renal failure and cardiovascular disease and non-hospitalized patients were tested by ELISA method using anti-Cys C obtained from mice Balb/C.

**Results:** Our findings indicated 0.36-2.4 mg/L as the best conclusion for antigen cystatin C in patients’ sera and 1/50 dilution for anti-Cys C obtained from mice Balb/C and showed a relationship between patients with high creatinine and high concentration of cystatin C. In case of five cardiovascular disease patients with normal upper limit of Creatinine we obtained cystatin C lower than kidney failure and raising of cystatin C in 6 patients with increased TSH were seen.

**Conclusions:** Polyclonal anti-Cys C antibodies were obtained through the immunization of Balb/C mice can be employed as an anti-Cys C in ELISA for diagnosis of some renal dysfunctions.


**Introduction**

Chronic kidney disease is a worldwide health problem that carries a substantial risk for cardiovascular morbidity and death. Current guidelines define chronic kidney disease as kidney damage or glomerular filtration rate (GFR) less than 60 mL/min/1.73 m² for 3 months or more, regardless of cause. GFR is the most frequently used criteria in the assessment of renal function.1,3

GFR is measured by using a clearance determined by a biologically inert substance freely filtered through the glomerular membrane and re-entering circulation. Determination of creatinine clearance is the most widely used method for non-invasive estimation of GFR. However, creatinine evaluation is influenced by muscle mass, body surface and food intake; therefore, one must consider age, sex, height, and body composition when evaluating patient sample. Creatinine clearance leads to significant over estimation on GFR in those patients with highly decreased GFR due to tubular secretion. The collection of 24-hour urine is time consuming and creates additional sources of errors.4

But cystatin C produced at a constant rate and the production rate in humans is remarkably constant over the entire lifetime. Elimination from the circulation is almost entirely via glomerular filtration. For this reason the serum
Cystatin C is a member of type 2 cystatin superfamily and a basic proteinase inhibitor with a low molecular weight of 13 kDa that produced by all human nucleated cells and is found in high concentrations in biological fluids. Cystatin C is freely filtered by the glomerulus and is not selected by the tubular cells and is reabsorbed by the tubular epithelial cells and is subsequently catabolized. Therefore, the serum cystatin C concentration may be considered as an endogenous marker of the GFR. Meanwhile, the use of cystatin C is interfered by non-renal factors such as glucocorticoid therapy, malignancy or thyroid disorders, which influence serum cystatin C concentrations. Cystatin C is a superfamily of cystatin proteinases found in both plants and animals. They comprise a group of proteinase inhibitors, widely distributed in tissues and body fluids and from tight complexes with cysteine proteases such as cathepsin H, L, and S. Cystatin C is thought to serve an important physiological role as a local regulator of this enzymatic activity. Cystatin C is increased in patients with malignant disease and is related to the insufficiency of renal function and appears to be a better marker than creatinine. The blood concentration of cystatin C depends on the GFR. On the other hand, low levels of cystatin C involves causing the breakdown of the elastic laminae and subsequently, the atherosclerosis and abdominal aortic aneurysm. Changes in cystatin C have been demonstrated in a number of cardiovascular diseases, including atherosclerosis, amyotrophic lateral sclerosis (ALS) and myocardial infarction. Plasma cystatin C has also been reported to be a useful tool in the detection of incipient nephropathy in patients with non-insulin dependent diabetes mellitus. Thus thyroid function has a major impact on cystatin C levels. Concentration of cystatin C is interfered by non-renal factors, such as glucocorticoid therapy, malignancy, cyclosporins, hyperhomocysteineemia, liver disease, heart failure. The aim of this study was to examine the application of mouse polyAb against cystatin C protein patient serum in indirect enzyme-linked immunosorbent assay (ELISA) that by recombinant antigen cystatin C in Balb/C mice has been produced. As screened cystatin C antigen in positive cases by a mouse polyAb against for diagnosis of some of disorders especially renal dysfunction.

Materials and Methods

Specimens
A total of 68 serum from 36 healthy and 32 patients were obtained hospitalized with renal failure and cardiovascular disease and non-hospitalized patients from Modares hospital, Tehran, Iran. Serum samples were collected and stored at -70°C until analyzed.

Construct Design

Related sequences, human cystatin C molecule consists of a single polypeptide chain of 120 amino acids with molecular mass of 13 kDa and is a non-glycosylated, basic protein which has 2 disulfide bridges located near the carboxyl terminus. The protein contains an extra His-tag at N-terminus. The sequence obtained through other bioinformatics methods were studied and the second and third structure of mRNA and protein produced by it were investigated. Optimized sequence after evaluation was ordered for synthesis.

Preparation and Confirmation of Recombinant CysC Protein

The CysC gene (GenBank accession no NM_000099) was optimized according to codon usage bases of Escherichia coli and synthesized in pUC57 vector (Biomatik). Synthesized sequence was BamHI and HindIII digested and inserted into similarly digested pET-28a (+) using T4 ligase (Fermentas, Germany) to generate pET-28a (+)-CysC plasmid. After each digestion the fragments were purified with GeneJET Gel Extraction Kit (Fermentas, # K0691). Plasmid isolation was carried out using GeneJET Plasmid MiniPrep Kit (Fermentas, # K0502) as per the manufacturer’s protocol. E. coli BL21 (DE3) was used as a host cell transformed by micro-pulsar (Bio-Rad) at 1200 and in a 0.1 cm electroporation cuvette. Preparation of electrocomitant cells and electroporation were carried out as described in Bio-Rad’s MicroPulsor Electroporation Apparatus Operating Instructions and Applications Guide (Bio-Rad, #165-2100). The cells were plated onto LB plates containing 40 μg/μL kanamycin to obtain positively transformed colonies. Transformants were confirmed using polymerase chain reaction (PCR) technique by T7-promter-primer and T7-Terminal-primer for pET-28a (+), and double-digestion by restriction enzymes. Amplification was made in a total volume of 25 μL of reaction mixture containing 0.3 μL of genomic DNA (0.5 μg/μL), 2 μL of 10× Taq polymerase buffer, 0.8 μL MgCl₂ (25 mM), 0.4 μL dNTP Mix (10 mM each), 0.4 μL of each primer (25 pmol) and 1 μL Taq polymerase PCR mix. A total of 30 cycles was performed with the first denaturation at 95°C for 15 seconds, then 30 cycles at 94°C for 50 seconds, 59°C for 50 seconds and 72°C for 1 minute, and the final extension at 72°C for 3 minutes. The amplified products were analyzed by electrophoresis with a 1% agarose gel containing SYBR green and UV-transilluminator visualization.

Cells harboring recombinant plasmids were induced with 1 mM isopropyl-D-thiogalactopyranoside (IPTG) when cells were grown to an OD₆₀₀ = 0.6 and cultured at 37°C for 5 hours and SDS-PAGE 15% was applied to verify Cys C expression.

Cys C Purification Using Nickel Affinity Column

Induced colony harboring pET-28a (+)-CysC plasmid was used for protein purification. The bacterial samples were given off before and after the induction and analyzed by using sodium dodecyl-sulfate-poly acrylamide gel electrophoresis.
Enzyme-Linked Immunosorbent Assay Analysis (ELISA) was performed to quantify Cystatin C in patients’ sera. Microplates were coated with 5 µg human sera Cys C protein from 32 hospitalized patients with renal failure and cardiovascular disease and non-hospitalized patients referred to Modares hospital, followed by incubation for overnight at 4°C. The reaction wells were blocked with 3% BSA solution for 45 minutes at 37°C. Plates were washed with PBST for three times, and then treated with anti-human Cys C obtained from mouse Balb/C that was diluted to 1:50 in coating buffer (pH 9.6) and incubated for 60 minutes at 37°C, then 1/5000 diluted anti-mouse IgG conjugated with peroxidase conjugate at a dilution of 1:5000 as the second antibody for 1 hour on the vibrator in the dark. Adding OPD as a peroxidase substrate, and then the reaction was stopped by 100 µL of TMB solution for the readout at 450 nm to visualize the antigen–antibody reaction ELISA test to quantify Cystatin C in patients’ sera was performed as described above.

Statistical Analysis
All Statistical analysis was performed using SPSS software (version 16.0; SPSS, Inc.) and data analysis software (Microsoft Excel 2007). P value of < 0.05 was considered as statistically significant.

Ethical Considerations
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments.
Results

To develop an ELISA test to detect Cys C antigens in human sera, an antigenic sequence CysC was constructed (120 amino acids). The bioinformatics results showed that the construct was stable and immunogenic domain was exposed (data not shown).

The fragments digested from pUC57-CysC were cloned into digested pET-28a (+) vectors. Released fragment from pET-28a (+)-CysC with 2 BanHI and HindIII restriction enzymes (Figure 1A) and the 360 bp of the CysC gene isolated through PCR (Figure 1B) indicate the successful cloning of the CysC gene. The 13 kDa CysC protein detected in expressed protein (Figure 2) and purified by chromatography using Ni-NTA agarose (Qiagen) (Figure 3) and confirmed by appearing a proper band by Western blotting (Figure 4). Protein concentration measured by chemiluminescence and turbidimetry was 5.01 and 8 µg/mL, respectively. Mice were immunized with recombinant Cyc C protein complete and incomplete Freund’s adjuvants three times within 6 weeks. The sera were collected after immunization and assessed for Cys C specific IgG by ELISA method (Figure 4). Non-immunized mice sera were used as control (P < 0.05). 1/50 dilution resulted in the optimum density. A standard plot curve from serial dilution of Cys C was obtained, which indicates a relationship between optical density and cystatin C recombinant protein to estimate the Cys C protein in patient’s sera (Figure 5). The optimum dilution of anti-Cys C (1:50) was used to calculate the concentration of Cys C for 32 patients led to a maximum optical density in patients with acute and chronic renal failure and the minimum amount in patients (Figure 6). ELISA were estimated based on comparing their optical densities with the standard curve with sample test to calculate the relative amount of Cys C antigen present in the serum patients. The cutoff values of 0.36-2.4 µg/mL were considered levels of pre-treatment for Cys C antigens, respectively, sensitivity (95%), and specificity (98%) were determined by SPSS analysis.

Discussion

Cystatin C or cystatin 3 is a protein encoded by the CST3 gene, was originally described as a constituent of normal cerebrospinal fluid (CSF) and of urine from patients with renal failure. In humans, all cells with nucleus produce cystatin C as a chain of 120 amino acids. It is found in virtually all tissues and bodily fluids. Cystatin C, which belongs to the type II cystatin gene family, is a potent inhibitor of lysosomal proteinases and probably one of the most important extracellular inhibitor of cysteine proteases.27,28 Cystatin C is freely filtered through the glomerulus, is not secreted by the tubule or eliminated via any extra renal route, and is almost completely absorbed and metabolized by proximal tubular cells. Therefore, the plasma concentration of cystatin C is almost exclusively determined by the GFR, making cystatin C an excellent indicator of GFR. Cystatin C has advantages over routine clinical measures of renal function. It is more accurate than plasma creatinine and the Cockcroft-Gault estimation of creatinine clearance and is more reliable than the 24 hours creatinine clearance. There is a growing body of evidence that suggests that cystatin C can be used to detect kidney disease at earlier stages than serum creatinine which may help facilitate prevention efforts in the elderly and those with diabetes, hypertension,
Recombinant Expression of Human Cystatin C Biomarker

or cardiovascular, as well as its relation to disease involving amyloid such as Alzheimer.\textsuperscript{1,27}

Moreover, cystatin C is involved in network reorganization in the epileptic dentate gyrus. The standard method used in this ELISA is recombinant human cystatin C, consisting of 120 amino acids with the molecular mass nearly 13 kDa. Rapid determination of renal function followed by timely therapy could improve patient care. Human cystatin C seems to be an excellent marker of renal function, available evidence demonstrated that serum cystatin C is superior to serum creatinine as a marker of GFR, particularly in identifying initial small decreases in GFR. In contrast to serum creatinine, serum cystatin C in unaffected by muscle mass, age, gender or race and it is not affected by most drugs, infections, diet or inflammation.\textsuperscript{29,30} Cystatin C has been associated with hyperhomocysteinemia, which is found in renal transplant patients and it has been shown to increase with the progression of liver disease.\textsuperscript{31} The human cystatin family comprises 11 identified proteins. Two of these, cystatin A and B form the family 1 cystatins and are mainly intracellular proteins, but cystatins C, D, E, F, S, SA and SN are mainly extracellular or transcellular proteins and constitute the family 2 cystatins (http://www.slideshare.net/ksodhi21/cystatin-c-2014). The family 3 cystatins, high and low molecular weight kininogen, contain three cystatin domains and mainly intravascular proteins, which in addition to being inhibitors of cysteine proteases also are involved in the coagulation process and in the production of vasoactive peptides.\textsuperscript{32}

In this study, His-tagged human cystatin C was expressed in \textit{E. coli} BL21 (DE3). After 3 hours induction with 1 mM IPTG at 37°C, the cells harvested and subjected to ultrasonic treatment. The sonicated extract was separated into soluble and insoluble fractions by centrifugation at 14000 rpm for 30min at 4°C. Expressed proteins in \textit{E. coli} were analyzed by SDS-PAGE 15% and coomassie brilliant blue staining. SDS-PAGE analysis result is shown in Figure 1. The presence of a predominant induction band with molecular weight around 15 kDa (between 10-17 kDa) after purifying the fusion protein human cystatin C with affinity chromatography, each fraction was collected manually, and the fractions were analyzed by SDS-PAGE and western blotting procedures (Figures 2, 3 and 4). In our study, a relatively high amount of the cystatin C fusion protein was obtained in the soluble form, while some amount of the fusion protein was also found in the inclusion body. In this study mice Balb/C were injected with recombinant protein cystatin C using complete and incomplete Freund’s adjuvants three times within 6 weeks and then sera were collected to assess specific antibodies after immunization and detect protein cystatin C in patients with chronic kidney disease (CKD) and some of disease. To set up a reliable ELISA method and determine sensitivity and specificity of ELISA, One ELISA was designated for qualifying human cystatin C antigen in patient’s sera. Recombinant protein with coating buffer was prepared as serial dilution (1:2 to 1:64) and the best response for ELISA obtained at dilution of 1:4 for antigen. Consequently to optimize the best dilution of anti-cystatin C were diluted (1:5 to 1:100) while concentration of antigen was remained constant and resulted in the best conclusion at dilution of 1:50 for anti-cystatin C. After coating 5 µg recombinant protein and preparation of serial dilution for antigen we obtained a curve based on optical densities against concentration of cystatin C which it can used to estimate cystatin C values in patients sera.

Conclusions

Our findings indicated a relationship between patients with high creatinine (19 patients) and high concentration of...
Cystatin C. In case of five cardiovascular disease patients with normal upper limit of creatinine we obtained cystatin C lower than kidney failure and raising of cystatin C in 6 patient with increased thyroid-stimulating hormone (TSH) were seen. Consequently, polyclonal anti-Cys C antibodies were obtained through the immunization of Balb/C mice with human recombinant cystatin C expressed in E. coli can be employed as an anti-Cys C in ELISA for diagnosis of some of disorders especially renal dysfunction.

Acknowledgments
The authors thank from colleagues in Applied Biotechnology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Science, for their helpful discussions.

Conflict of Interest Disclosures
The authors declare they have no conflicts of interest.

References
10. Assafelizadeh MA, Sankian M, Jabbari F, Tehrani M, Varasteh A. Expression of the recombinant major allergen of Salsola kali pollen (Sal k 1) and comparison with its low-immunoglobulin E-binding mutant. Allergol Int. 2010;59(2):213-222. doi: 10.2332/allergolint.09.OA-0155